TOLVAPTAN
Total Payments
$16.8M
Transactions
1,346
Doctors
170
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $674,849 | 117 | 17 |
| 2023 | $1.5M | 181 | 25 |
| 2022 | $893,510 | 141 | 30 |
| 2021 | $555,528 | 93 | 22 |
| 2019 | $65,589 | 10 | 2 |
| 2018 | $4.0M | 355 | 91 |
| 2017 | $9.1M | 449 | 84 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14.4M | 352 | 85.7% |
| Consulting Fee | $2.2M | 460 | 13.3% |
| Travel and Lodging | $127,012 | 207 | 0.8% |
| Grant | $24,583 | 1 | 0.1% |
| Food and Beverage | $17,604 | 320 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,765 | 6 | 0.0% |
Payments by Type
Research
$14.4M
352 transactions
General
$2.4M
994 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| OPEN-LABEL TRIAL TO EVALUATE THE LONG TERM SAFETY OF TITRATED IMMEDIATE-RELEASE TOLVAPTAN IN SUBJECTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $7.0M | 1 |
| A PHASE 3B, MULTI-CENTER, OPEN-LABEL TRIAL TO EVALUATE THE LONG TERM SAFETY OF TITRATED IMMEDIATE-RELEASE TOLVAPTAN OPC-41061, 30 MG TO 120 MGDAY, SPLIT DOSE IN SUBJECTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $3.7M | 3 |
| EFFICACY AND SAFETY OF TOLVAPTAN IN SUBJECTS WITH CHRONIC KIDNEY DISEASE BETWEEN LATE STAGE 2 TO EARLY STAGE 4 DUE TO AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1.8M | 7 |
| A PHASE 3B MULTICENTER OPEN-LABEL TRIAL OF THE SAFETY, TOLERABILITY, AND EFFICACY OF TOLVAPTAN IN INFANTS AND CHILDREN 28 DAYS TO LESS THAN 18 YEARS OF AGE WITH AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) | Otsuka Pharmaceutical Development & Commercialization, Inc. | $476,344 | 0 |
| REAL WORLD EFFECTIVENESS OF JYNARQUE AMONG ADPKD PATIENTS TREATED IN IDN'S | Otsuka Pharmaceutical Development & Commercialization, Inc. | $385,022 | 0 |
| A PHASE 3B MULTICENTER OPEN-LABEL TRIAL OF THE SAFETY, TOLERABILITY, AND EFFICACY OF TOLVAPTAN IN INFANTS AND CHILDREN 28 DAYS TO LESS THAN 12 WEEKS OF AGE WITH AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) | Otsuka Pharmaceutical Development & Commercialization, Inc. | $355,250 | 3 |
| A MULTI-CENTER, OPEN-LABEL, EXPLORATORY STUDY TO ASSESS THE EFFICACY OF PROBENECID IN DECREASING THE URINE OUTPUT AND INCREASING THE URINE OSMOLALITY IN PATIENTS WITH HEREDITARY NEPHROGENIC DIABETES INSIPIDUS, PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE TREATED WITH TOLVAPTAN, AND SEVERELY POLYURIC PATIENTS WITH PREVIOUS LITHIUM ADMINISTRATION (MAYO CLINIC; DR. FOUAD CHEBIB) | Otsuka Pharmaceutical Development & Commercialization, Inc. | $209,885 | 0 |
| Extraction of real-time ADPKD outcomes from a large electronic health record dataset | Otsuka Pharmaceutical Development & Commercialization, Inc. | $130,338 | 0 |
| USING CULTURALLY-SENSITIVE DISCUSSIONS AND GENETIC TESTING TO IMPROVE ACCESS TO EARLY ADPKD CARE AND IMPROVE HEALTH DISPARITIES | Otsuka Pharmaceutical Development & Commercialization, Inc. | $100,000 | 0 |
| A PHASE 3B, MULTI-CENTER, RANDOMIZED-WITHDRAWAL, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP TRIAL TO COMPARE THE EFFICACY AND SAFETY OF TOLVAPTAN 45 TO 120 MGDAY, SPLIT-DOSE IN SUBJECTS WITH CHRONIC KIDNEY DISEASE BETWEEN LATE STAGE 2 TO EARLY STAGE 4 DUE TO AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $77,719 | 1 |
| Effects of combination therapy with Tolvaptan and the Farnesoid X receptor agonist INT-747 on hepatotoxicity, metabolic and injury biomakers, and cystogenesis in ADPKD. | Otsuka Pharmaceutical Development & Commercialization, Inc. | $43,750 | 0 |
| TOLVAPTAN FOR WORSENING OUTPATIENT HEART FAILURE ROLE OF COPEPTIN IN IDENTIFYING RESPONDERS TROUPER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $34,141 | 0 |
| OPEN-LABEL TOLVAPTAN STUDY IN SUBJECTS WITH ADPKD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $20,183 | 0 |
| A PHASE 3B, TWO-PART, MULTICENTER, ONE YEAR RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF THE SAFETY, PHARMACOKINETICS, TOLERABILITY, AND EFFICACY OF TOLVAPTAN FOLLOWED BY A TWO YEAR OPEN-LABEL EXTENSION IN CHILDREN AND ADOLESCENT SUBJECTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE ADPKD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $2,900 | 9 |
| Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,980 | 0 |
| Development of and Event-based Diary for Patients with ADPKD - Clinician Interviews | Otsuka Pharmaceutical Development & Commercialization, Inc. | $650.00 | 2 |
| A Phase 3b, Two-part, Multicenter, One Year Randomized, Double-blind, Placebo controlled Trial of the Safety, Pharmacokinetics, Tolerability, and Efficacy of Tolvaptan followed by a Two Year Open-label Extension in Children and Adolescent Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Otsuka Pharmaceutical Development & Commercialization, Inc. | $300.00 | 1 |
Top Doctors Receiving Payments for TOLVAPTAN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Charlottesville, VA | $14.4M | 321 |
| , M.D | Dermatology | Hoboken, NJ | $1.2M | 39 |
| , MD | Gastroenterology | Saint Louis, MO | $137,582 | 70 |
| , MD | Internal Medicine | Farmington, CT | $85,995 | 15 |
| James Lewis | Gastroenterology | Washington, DC | $76,742 | 60 |
| , M.D | Gastroenterology | Chapel Hill, NC | $53,312 | 49 |
| , M.D | Gastroenterology | Farmington, CT | $49,700 | 42 |
| , MD | Nephrology | Boston, MA | $45,442 | 24 |
| Arlene Chapman | Nephrology | Burr Ridge, IL | $41,512 | 18 |
| , MD | Pediatric Nephrology | Cincinnati, OH | $38,416 | 20 |
| , MD | Pediatric Nephrology | Washington, DC | $37,177 | 17 |
| , M.D | Internal Medicine | Rochester, MN | $33,613 | 23 |
| , MD | Nephrology | San Francisco, CA | $32,707 | 14 |
| , MD | Nephrology | New Haven, CT | $26,933 | 20 |
| , MD | Specialist | Arlington, TX | $26,870 | 2 |
| , MD, PHD | Pediatric Nephrology | Atlanta, GA | $25,818 | 11 |
| Michal Mrug | Nephrology | Birmingham, AL | $24,220 | 14 |
| , M.D | Nephrology | Orange, CA | $18,744 | 13 |
| , MD | Nephrology | Atlanta, GA | $18,211 | 17 |
| , M.D | Nephrology | Rochester, MN | $16,796 | 4 |
| , M.D | Pediatrics | Hershey, PA | $16,184 | 3 |
| , M.D | Internal Medicine | Los Angeles, CA | $15,561 | 11 |
| , M.D | Diagnostic Radiology | El Paso, TX | $13,908 | 7 |
| , M.D | Nephrology | Rochester, MN | $12,541 | 12 |
| , M.D | Internal Medicine | Houston, TX | $12,374 | 15 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $16.8M
- Total Doctors 170
- Transactions 1,346
About TOLVAPTAN
TOLVAPTAN is a drug associated with $16.8M in payments to 170 healthcare providers, recorded across 1,346 transactions in the CMS Open Payments database. The primary manufacturer is Otsuka Pharmaceutical Development & Commercialization, Inc..
Payment data is available from 2017 to 2024. In 2024, $674,849 was paid across 117 transactions to 17 doctors.
The most common payment nature for TOLVAPTAN is "Unspecified" ($14.4M, 85.7% of total).
TOLVAPTAN is associated with 17 research studies, including "OPEN-LABEL TRIAL TO EVALUATE THE LONG TERM SAFETY OF TITRATED IMMEDIATE-RELEASE TOLVAPTAN IN SUBJECTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE" ($7.0M).